Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9478	Companies
185482	Keywords
117825	Articles
99322	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 06/09/2025 at 22:20, 5 months 25 days ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
PRESS RELEASE

published on 06/09/2025 at 22:15, 5 months 25 days ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population
BRIEF

published on 06/09/2025 at 15:05, 5 months 26 days ago

Jaguar Health Discusses Crofelemer Pathway with FDA

Crofelemer FDA Approval Orphan Drug Designation Metastatic Breast Cancer Expanded Access Program
PRESS RELEASE

published on 06/09/2025 at 15:00, 5 months 26 days ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting

Napo Pharmaceuticals Crofelemer Jaguar Health Cancer Therapy Metastatic Breast Cancer
BRIEF

published on 06/06/2025 at 15:05, 5 months 29 days ago

Jaguar Health to Discuss Orphan Disease Efforts in Upcoming Fireside Chat

Napo Pharmaceuticals Crofelemer Jaguar Health Fireside Chat Orphan Disease
PRESS RELEASE

published on 06/06/2025 at 15:00, 5 months 29 days ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health's CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025 to discuss the company's orphan disease development programs

Pharmaceuticals Jaguar Health Lisa Conte Virtual Fireside Chat Orphan Disease Development
BRIEF

published on 05/21/2025 at 14:05, 6 months 15 days ago

Jaguar Health Conducts $1.5M Registered Direct Offering

Private Placement Nasdaq Jaguar Health Common Stock Direct Offering
PRESS RELEASE

published on 05/21/2025 at 14:00, 6 months 15 days ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces purchase of 246,306 shares of common stock at $6.09 per share in a registered direct offering. H.C. Wainwright & Co. serves as exclusive placement agent

Shares Stock Purchase Jaguar Health H.C. Wainwright & Co. Direct Offering
BRIEF

published on 05/20/2025 at 15:20, 6 months 16 days ago

Jaguar Health Begins Phase 2 Trial for Crofelemer in Pediatric MVID Patients

Crofelemer Jaguar Health Phase 2 Trial MVID Pediatric Treatment
PRESS RELEASE

published on 05/20/2025 at 15:15, 6 months 16 days ago

First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Jaguar Health's crofelemer shows promise in reducing total parenteral support in pediatric MVID patient. Ongoing trials and future expectations discussed

Crofelemer Clinical Trials Jaguar Health Pediatric MVID Total Parenteral Support

Accesswire

Published on 12/05/2025 at 15:25, 12 minutes ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 37 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 37 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 37 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 13 hours 2 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 15:05, 32 minutes ago

Seegene Establishes French Subsidiary to Expand European Footprint
Published on 12/05/2025 at 14:22, 1 hour 15 minutes ago

EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 1 hour 20 minutes ago

Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 1 hour 27 minutes ago

The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 1 hour 52 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings

Les Echos

Published on 12/05/2025 at 15:10, 26 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 6 hours 52 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 21 hours 37 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 21 hours 52 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 21 hours 53 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE